Ser1179
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser1179  -  eNOS (human)

Site Information
RIRtQsFsLQERQLR   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 467802

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 2 ) , mutation of modification site ( 4 ) , phospho-antibody ( 4 ) , western blotting ( 4 )
Disease tissue studied:
lung cancer ( 2 ) , non-small cell lung adenocarcinoma ( 2 ) , pancreatic ductal adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:
'pancreatic, ductal'-pancreas ( 1 ) , HUVEC (endothelial) ( 4 ) , lung ( 2 )

Upstream Regulation
Treatments:
simvastatin ( 4 ) , VEGF ( 4 ) , wortmannin ( 4 )

Downstream Regulation
Effects of modification on eNOS:
enzymatic activity, induced ( 4 )
Effects of modification on biological processes:
apoptosis, inhibited ( 4 )

References 

1

Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948
24670416   Curated Info

2

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

3

Shiromizu T, et al. (2013) Identification of missing proteins in the neXtProt database and unregistered phosphopeptides in the PhosphoSitePlus database as part of the Chromosome-centric Human Proteome Project. J Proteome Res 12, 2414-21
23312004   Curated Info

4

Kureishi Y, et al. (2000) The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med 6, 1004-10
10973320   Curated Info